Opus Genetics, Inc. reported topline results from its Phase 3 trial of Phentolamine Ophthalmic Solution for presbyopia on June 26, 2025, indicating promising advancements in their treatment options. The company also confirmed that its cash runway is adequate to sustain operations into the second half of fiscal year 2026.